Literature DB >> 21524335

Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain.

Jérôme Maheux1, Laura Vuillier, Mylène Mahfouz, Claude Rouillard, Daniel Lévesque.   

Abstract

Different patterns of expression of the transcription factors of Nur77 and Nor-1 are induced following acute administration of typical and atypical antipsychotic drugs. The pharmacological profile of atypical antipsychotics suggests that serotonergic and/or adrenergic receptors might contribute to these reported differences. In order to test this possibility, we examined the abilities of serotonin 5-HT(1A) and 5-HT(2A/2C), and α₁- and α₂-adrenergic receptor drugs to modify the pattern of Nur77 (NR4A1) and Nor-1 (NR4A3) mRNA expression induced by haloperidol. Various groups of mice were treated with either saline, DOI, a 5-HT(2A/2C) agonist, MDL11939, a 5-HT(2A) antagonist, 8-OH-DPAT, a 5-HT(1A) agonist, prazosin, an α₁-adrenergic antagonist and idazoxan, an α₂-adrenergic antagonist, alone or in combination with haloperidol. The 5-HT(2A/2C) agonist DOI alone significantly increased Nur77 expression in the medial striatum and nucleus accumbens. DOI reduced Nor-1 expression, while MDL11939 increased the expression of this transcript in the cortex. Prazosin reduced Nur77 expression in the dorsal striatum and nucleus accumbens. Interestingly, 8-OH-DPAT and MDL11939 partially prevented haloperidol-induced Nur77 up-regulation, while MDL11939 completely abolished Nor-1 expression in the striatum. In addition, MDL11939 decreased haloperidol-induced Nur77 and Nor-1 mRNA levels in the ventral tegmental area. On the contrary, idazoxan (α₂ antagonist) consistently potentiated haloperidol-induced Nur77, but not Nor-1 mRNA levels in the striatum, whereas prazosin (α₁ antagonist) remained without effect. Taken together, these results show the ability of a 5-HT(1A) agonist or a 5-HT(2A) antagonist to reduce haloperidol-induced Nur77 and Nor-1 striatal expression, suggesting that these serotonin receptor subtypes participate in the differential pattern of gene expression induced by typical and atypical antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524335      PMCID: PMC4807123          DOI: 10.1017/S1461145711000630

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  49 in total

Review 1.  New antipsychotics and schizophrenia: a review on efficacy and side effects.

Authors:  Alessandro Serretti; Diana De Ronchi; Cristina Lorenzi; Domenico Berardi
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation.

Authors:  Daniel Lévesque; Claude Rouillard
Journal:  Trends Neurosci       Date:  2006-11-28       Impact factor: 13.837

4.  Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover.

Authors:  François Gilbert; Marc Morissette; Michel St-Hilaire; Brigitte Paquet; Claude Rouillard; Thérèse Di Paolo; Daniel Lévesque
Journal:  Biol Psychiatry       Date:  2006-08-07       Impact factor: 13.382

5.  Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.

Authors:  Michel St-Hilaire; Emmanuelle Bourhis; Daniel Lévesque; Claude Rouillard
Journal:  Eur J Neurosci       Date:  2006-08       Impact factor: 3.386

6.  Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain.

Authors:  M C Langlois; G Beaudry; H Zekki; C Rouillard; D Lévesque
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

Authors:  Monica M Marcus; Kent E Jardemark; Marie-Louise Wadenberg; Xavier Langlois; Peter Hertel; Torgny H Svensson
Journal:  Int J Neuropsychopharmacol       Date:  2005-04-28       Impact factor: 5.176

8.  The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms.

Authors:  Roberto W Invernizzi; Claudio Garavaglia; Rosario Samanin
Journal:  Neuropsychopharmacology       Date:  2003-03-19       Impact factor: 7.853

9.  nor-1 regulates hippocampal axon guidance, pyramidal cell survival, and seizure susceptibility.

Authors:  Tiia Pönniö; Orla M Conneely
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 10.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

View more
  3 in total

1.  Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.

Authors:  Souha Mahmoudi; Pierre J Blanchet; Daniel Lévesque
Journal:  Eur J Neurosci       Date:  2013-03-31       Impact factor: 3.386

2.  17β-estradiol delays 6-OHDA-induced apoptosis by acting on Nur77 translocation from the nucleus to the cytoplasm.

Authors:  Justine Renaud; Keith Chiasson; Julie Bournival; Claude Rouillard; Maria-Grazia Martinoli
Journal:  Neurotox Res       Date:  2013-11-26       Impact factor: 3.911

Review 3.  Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes.

Authors:  Andrea de Bartolomeis; Elisabetta F Buonaguro; Gianmarco Latte; Rodolfo Rossi; Federica Marmo; Felice Iasevoli; Carmine Tomasetti
Journal:  Front Behav Neurosci       Date:  2017-12-11       Impact factor: 3.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.